New article | Biomarkers for canine mammary neoplasia

| Mai 2023 | New Article: Galadima et al. used the scioCD assay to analyse canine blood samples in the context of mammary neoplasia. The proteins CD20, CD45RA and CD99 were found at altered levels. The findings were validated by Western Blotting and are suggested as novel serum biomarkers.

Galadima et al. Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99 (2023) Int. J. Mol. Sci. 24(11)

Powering breakthrough research using Multiomics



Multi-Omics collaboration of Singleron and Sciomics


Powering breakthrough research using Multiomics


Singleron and Sciomics – Collaborating in the pursuit of Precision Medicine

Singleron Biotechnologies and Sciomics have a common goal: Precision Medicine. Their scientific approaches, however, seem to come from two sides of a coin. Consequently, their strategic alliance is expected to reach complementary and interlocking scientific findings in the quest of holistic disease research.

Cologne and Heidelberg, Germany, 30 May 2023

Singleron Biotechnologies, a front-runner in single cell multi-omics sequencing solutions and Sciomics, a first-class provider of explorative proteomic and post translational modification profiling platforms, announce their collaboration to advance Precision Medicine.

Singleron Biotechnologies is an innovative single cell sequencing solution provider with a focus on molecular diagnostics. They apply ground-breaking single cell analysis techniques for clinical diagnosis, drug development, and health management. Sciomics’ powerful proteomic and post-translational modification profiling platform provides in-depth insights on protein levels to clients from biotech and pharma industry and is internally used to develop innovative biomarker signatures.

At Singleron we believe that single cell sequencing and analysis is vital to understand complex disease mechanisms to evolve increasingly individualized medicine” said Dr. Andreas Schmidt, Senior Vice President of Global Business Development at Singleron. “This new relationship between Singleron and Sciomics offers a synergistic approach to understand the multiple layers of cellular regulation.

Over the last decade we developed an efficient and robust platform for profiling protein levels and phosphorylation status.”, said Dr. Christoph Schröder, Chief Executive Officer at Sciomics. “By combining multiple omics technologies, we believe significant advances can be facilitated in the area of precision medicine.

Together, their strategically combined expertise integrates single cell analyses with cutting-edge technology for biomarkers, profiling pathway activity and soluble markers and is expected to deliver innovative and novel insights accelerating advancements in personalized medicine promoting human health.

About Singleron

Founded in 2018, Singleron develops and commercializes single cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single cell analysis. Singleron’s sample services offer expert execution and generation of high-quality results for academia, clinics, and biotech.

The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 2,000 laboratories in hospitals, research institutes, and pharmaceutical companies.

About Sciomics

Sciomics has extensive expertise in the field of biomarker discovery, in vitro and in vivo. Their model system characterisation and disease mechanism profiling use high-content protein and post-translational modification profiling. Currently, this results in over 1,400 analysed proteins by using their proprietary fully immuno-based scioDiscover antibody array platform in a single assay with minimal sample requirements combined with Machine Learning assisted data analysis. The high-content and high-throughput platform guarantees robust and reproducible results which can be easily translated into validation and clinical assays. Sciomics serves customers world-wide, focussing on the European and North American market.


Media contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.


New article | Microbiota influences chemotherapy in pancreatic cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)

The Sciomics data were instrumental in supporting our IP protection strategy

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

With the professional and fast support we were able to confirm our hypotheses

Dr. Felix Czernilofsky

Department of Medicine V, Heidelberg University Hospital,Heidelberg, Germany

"The scioCyto assay from Sciomics was a tremendous help in characterizing complex supernatants of in vitro tumor microenvironment models. With the professional, fast and friendly support from Ronny and colleagues we were able to confirm and extend our hypotheses. I am very happy to recommend the Sciomics experience!"

Product: scioCyto


New article | HAPLN1 potentiates peritoneal metastasis in pancreatic cancer

| April 2023 | New Article: Wiedmann et al. identified HAPLN1 as a prognostic marker and as a and as a driver for peritoneal metastasis in pancreatic cancer. Sciomics contributed a plasma protein profiling of a mouse model to support this exciting study.

Wiedmann L et al. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Nature Communications 14,2354 (2023)

Sciomics helped us to achieve some interesting phosphoproteome data in human osteoclasts

Dr. Bettina Grötsch

Department of Medicine 3 - Rheumatology and Immunology, University Clinics Erlangen, Erlangen, Germany

"Our lab is working with human osteoclast that were isolated and differentiated from human peripheral blood. Therefore, we were quite limited in cell numbers and protein content for our planned Phosphoprotein analyses. Nonetheless, Sciomics and especially Camille Lowy helped us a lot to test and improve our protein isolation techniques to achieve some interesting phosphoproteome data in human osteoclasts. We were really impressed by the detailed data report and their willingness to discuss and reanalyze the data repeatedly until we got the best results out of our measurements. Even several month after their first report, we could ask for help and suggestions with an immediate reply.  The phosphoproteome analyses completed our preliminary project data and are now published in Frontiers Immunology.  Altogether, we were very happy with the service of Sciomics and special thanks to Camille Lowy and Christoph Schröder who guided us through the whole process."

Product: scioPhospho
Publication: Grötsch B. et al. 2022 Front. Immunol. 13:958974 

New article | The Lifestyle Modifications Affect the Endometrial Proteome

| June 2022 | In a study by D. Abdulkhalikova et al. Endometrial Proteome changes werde identified impacted by Lifestyle modification in woman with Polycystic Ovarian Syndrome and Obesity.

Abdulkhalikova, DR. et al. The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity. Front. Endocrinol. 2022 in press.

The results were delivered promptly

Kyriaki BarmpaKyriaki Barmpa - Uni LU

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

Working with Sciomics has been very easy and efficient.

Alenka Djarmila Behsen, PhD candidate

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, NorwayAlenka Behsen

"The process of working with Ronny and his colleagues at Sciomics has been very easy and efficient. Response time is very quick and they are always available for meetings when you have more questions. Would definitely recommend working with Sciomics."

Product: scioCD


New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.

New article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)

The first step in the journey from imprecise drug therapy to precision medicine - REPO4EU’s Euro / Global Platform for Drug Repurposing

Neckargemünd, 9th August, 2022


The biotechnology company Sciomics GmbH, located in Neckargemünd, Germany, today announced its participation in an ambitious joint initiative selected and granted almost €23M by the European Commission as part of the Horizon Europe Programme.

REPO4EU’s ultimate goal is to build and grow an industry-level European online platform for validated precision drug repurposing with a global reach. This platform will operate as the go-to data hub for key information, training resources, matchmaking and cooperation in drug repurposing.

The platform will provide extensive expertise throughout the whole value chain in drug repurposing: from freedom-to-operate analysis to intellectual property protection and business development, health technology assessment, ethics and data governance considerations.  

During the next 7 years, 28 partners from 10 countries (The Netherlands, Germany, Austria, Spain, Sweden, Romania, Belgium, Portugal, Switzerland and the United States) will join forces to make REPO4EU a reality and create a unique platform for drug repurposing, pooling stakeholders and expertise at a global stage to create a “made in Europe”, fully-fledged infrastructure for drug repurposing. Sciomics will contribute to the initiative with its expertise and scioDiscover platform for protein biomarker discovery and verification as well as disease mechanism elucidation.


Drug repurposing 

But what exactly is drug repurposing? To answer this question, there is first a need to address the elephant in the room: to this day, we still rely on 19th century disease definitions – often named after specific organs, symptoms or even doctors –, when it has become painfully obvious that trying to compartmentalize the human body into small, completely isolated parts with no connection to one another is an extremely naïve endeavour.  

The truth is that our disease definitions are no longer valid – and the end of medicine as we know it is quickly approaching.  

Even though we have witnessed an exponential increase in the volume of drug discovery investments since the 80s, overall efficacy has stagnated in the pharmaceutical sector – there is currently no way of differentiating between patients who will benefit and those who will not, and unwanted side effects cannot be predicted reliably.  

The reason? There is a conceptual problem in how we define diseases and, consequently, in the way we currently approach drug development. Most underlying disease mechanisms are not understood and are thus rather treated symptomatically in an imprecise manner. 


Systems Medicine is organ-agnostic 

This philosophy lies at the core of what we call systems medicine: the ambition to map the full network of human diseases – the so-called diseasome – to unravel the hidden connections between mechanistically similar diseases. In the diseasome, diseases appear in clusters, indicating a common genetic origin through shared risk genes. These clusters radically change what we call a disease: now, the underlying causal molecular mechanism becomes our disease definition.

It all comes down to a very simple thought: if we can understand the underlying mechanisms that govern a specific disease, surely, we can repurpose drugs for another disease that shares some of those common elements?  

The answer is yes! Mechanism-based drug repurposing will revolutionize the way we approach drugs – it will help us find new uses for already registered drugs, increase precision and radically cut down on costs and time in the drug development process – jumping straight into clinical trials that are small, precise, innovatively designed and compliant with the highest safety and operational excellence standards.  


Curing diseases with high precision 

Chronic diseases are only chronic because we do not know how to cure them yet. REPO4EU’s organ-agnostic approach will push drug repurposing to its full potential by mixing Big Data, Artificial Intelligence-driven bioinformatics and Network Science with advanced cheminformatics to redefine diseases in a mechanism-based manner and repurpose drugs beyond their original target. 

REPO4EU will thereby unlock unprecedented breakthroughs in precision, efficacy and cost-effectiveness, de-risking drug repurposing and paving the way towards personalized therapies and ultimately, precision medicine.  

A resource for researchers, companies, healthcare providers, payers, and patients 

Whether you need to secure bioinformatics support for an unmet medical need, explore a registered compound or a specific mechanism; assess your freedom to operate, outline a patenting strategy or browse regulatory advice; liaise with a business partner, locate a clinical trial test site for phase I-III or craft a business plan... we have the experts and the experience to help you! 

RExPO22 - The 1st International Conference on Drug Repurposing 

REPO4EU will officially start this September, and what better way to kick things off than with a high-profile conference? We are delighted to present RExPO22, the very first instalment in our RExPO series of international conferences on drug repurposing.  

Networking has always been the prime focus of any scientific and business event and this one is both: high impact science and innovative business. Come join us September 2nd-3rd at Maastricht for two days of vibrant keynotes from world-renowned experts and busy discussion around the future of drug repurposing! 


Key contacts 

Coordinator: Prof. Dr. Harald HHW Schmidt, Maastricht University, This email address is being protected from spambots. You need JavaScript enabled to view it.

Sciomics: Dr. Christoph Schröder, Sciomics GmbH, This email address is being protected from spambots. You need JavaScript enabled to view it.

Communication: Diana Lopez, AUSTRALO, This email address is being protected from spambots. You need JavaScript enabled to view it.  

Project management office: Miriam Simon, concentris, This email address is being protected from spambots. You need JavaScript enabled to view it.


More Information:

REPO4EU initiative: https://repo4.eu
ExPO22 conference: https://repo4.eu/rexpo22-conference/ cropped repo4eu header 1 1

The cooperation with Sciomics was just excellent.

Dr. Anke König

Clinics for dermatology, venerology and allergology, University Clinics Frankfurt, Frankfurt, Germany

"We enjoyed working with Sciomics on various research projects related to inflammatory skin diseases. The cooperation with Sciomics was just excellent. In addition to processing the samples and compiling the data in a perfectly understandable way, Sciomics GmbH supports us with the entire interpretation and presentation of our results with lots of ideas beyond the usual level of corporate performance. We are looking forward to developing new ideas for further clinical studies together."

Product: scioDiscover